
Approved for use through 10/31/2002 OMB 0651-0032 Patent and Trademark Office US DEPARTMENT OF COMPARCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control augher PF268D1C1 Attorney Docket No. UTILITY First Inventor Wei et al. PATENT APPLICATION Title Human Hematopoietic-Specific Prote TRANSMITTAL (Only for new nonprovisional applications under 37 CFR + 1 53(b)) Express Mail Label No. Assistant Commissioner for Patents Box Patent Application Washington, DC 20231 APPLICATION ELEMENTS *ADDRESS TO:* See MPEP chapter 600 concerning utility patent application contents. 7. CD-ROM or CD-R in duplicate, large table or Computer 1. 🛛 Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission 2. Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27. a. Computer Readable Form (CRF) b. Specification Sequence Listing on [Total Pages: 54] 3. Specification i. CD-ROM or CD-R (2 copies); or (preferred arrangement set forth below)
- Descriptive title of the Invention ii. 🛛 paper [Total Pages: 4] Cross Reference to Related Applications Statements verifying identity of above copies Statement Regarding Fed sponsored R & D
 Reference to sequence listing, a table, or a computer program listing appendix ACCOMPANYING APPLICATION PARTS - Background of the Invention - Brief Summary of the Invention Assignment Papers (cover sheet & document(s)) - Brief Description of the Drawings (if filed) from prior Appl. Serial No. 08/837,029 [6 pages] Detailed Description Power of Attorney - Claim(s) 10. 37 CFR 3.73(b) Statement Abstract of the Disclosure 11. Tenglish Translation Document (if applicable) 4. 🛛 Drawing(s) (35 U.S.C. 113) [Total Sheets 12.

Information Disclosure Statement/ Form PTO/SB/08 5. 🛛 Oath or Declaration Copies of Citations 13. Preliminary Amendment a. Newly executed (original or copy) 14. Return Receipt Postcard (MPEP 503) b. Copy from a prior application (37 CFR 1.63(d)) (should be specifically itemized) (for continuation/divisional with Box 17 completed) 15. \(\propto\) Certified Copy of Priority Document(s) (if foreign priority is claimed) i. DELETION OF INVENTOR(S) 16. Other: Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR ' 1.63(d)(2) and 1.33(b). Application Data Sheet. See 37 CFR 1.76. [3 Pages] 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: of prior application No: 09/265,977, filed March 11, 1999 Continuation-in-Part (CIP) Continuation Divisional Examiner: Spector, L. Group/Art Unit: 1647 Prior application information: For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been madvertently omitted from the submitted application parts. 18. CORRESPONDENCE ADDRESS 22195 Correspondence address below Customer Number or Bar Code Label NAME ADDRESS ZIP CODE STATE CITY TELEPHONE FAX COUNTRY Registration No. (Attorney/Agent) 41,119 NAME (Print/Type) Jonathan L. Klein November 16, 2001 Date SIGNATURE

Burden Hour Statement/ This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231



Approved for use through 10/31/2002 OMB 0651-0032

Patent and Trademark Office U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Total amount of payment

\$2,084.00

Complete if Known Application Number Unassigned Herewith Filing Date First Named Inventor Wei et al. Unassigned Examiner Name Unassigned Group Art Unit PF268D1C1 Attorney Docket Number

METHOD OF PAYMENT							FEE CALCULATION (continued)					
1. The Commissioner is hereby authorized to charge							3. A	ADDITIO	ONAL		, and the second	
indicated fees and credit any overpayments to.								Large Entity		Small Entity		
Deposit Account Number 08-3425							Fee	Fee	Fee	Fee		
Deposit Account Name Human Genome Sciences, Inc.					Code	(\$)	Code	(\$)	Fee Description	Fee Paid		
Charge Any Additional Fee Required							105	130	205	65	Surcharge - late filing fee or oath	
Under 37 CFR §§ 1.16 and 1.17							127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
Applicant claims small entity status.							139	130	139	130	Non-English specification	
See 37 CFR 1.27							147	2,520	147	2,520	For filing a request for ex parte reexamination	
2 Payment Enclosed:							112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
Check Credit Card Money Order Other							113	1,840	113	1,840*	Requesting publication of SIR after Examiner action	ļ
FEE CALCULATION							115	110	215	55	Extension for reply within first month	
F BASIC FILING FEE							116	400	216	200	Extension for reply within second month	
Large I	Entity	Small	Entity				117	920	217	460	Extension for reply within third month	
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee De	scription	Fee Paid	118	1,440	218	720	Extension for reply within fourth month	
I 101	740	201	370	Utility fili	ng fee	\$740 00	128	1,960	228	980	Extension for reply within fifth month	
±106	330	206	165	Design fil	ing fee		119	320	219	160	Notice of appeal	
107	510	207	255	Plant filin	g fee		120	320	220	160	Filing a brief in support of an appeal	
₌₁ 108	740	208	370	Reissue fi	iling fee		121	280	221	140	Request for oral hearing	-
114	160	214	80	Provision	al filing fee		138	1,510	138	1,510	Petition to institute a public use hearing	
3			SUBTO	OTAL (1)		\$740.00	140	110	240	55	Petition to revive - unavoidable	
Extra CLAIM FEES Extra Fee from Fee Poid					141	1,280	241	640	Petition to revive - unintentional			
(±) ₹ (1)¥\$				Extra Claims	Fee from below	Fee Paid	142	1,280	242	640	Utility issue fee (or reissue)	
ași Γotal Cla	laims [76	-20** [56	\$18.00	\$1,008.00	143	460	243	230	Design issue fee	
Indepen	dent	7	-3**	4	\$84.00	\$336.00	144	620	244	310	Plant issue fee	
Claims Multiple	L Denen	dent	i		\$280.00		122	130	122	130	Petitions to the Commissioner	
Multiple Dependent \$280.00						L	123	50	123	50	Processing fee under 37 CFR 1.17(q)	
							126	180	126	180	Submission of Information Disclosure Statement	
							581	40	581	40	Recording each patent assignment per property (times number of properties)	
Large Entity Small Entity			146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))					
Fee Code	Fee (\$)	Fee Code	Fee (\$)				149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
103	18	203	9	Claims in e	excess of 20		179	740	279	370	Request for Continued Examination (RCE)	
102	84	202	42	Independer	nt claims in e	ccess of 3	169	900	169	900	Request for expedited examination of a design application	
104	280	204	140		ependent clair		145	100	145	100	Certificate of correction	
108	84	209	42	** Reissue original	e independent I patent	claims over	148	110	248	55	Statutory disclaimer	
110 18 210 9 **		** Reissue	* Reissue claims in excess of 20 and over original patent		561	3	561	3	Printed copy of patent, regular service			
and over original patent					Other	Other fee (specify):						
SUBTOTAL (2) \$1,344.00						1,344.00	Other	fee (specify	·):			
or number previously paid, if greater; For Reissues, see above						ee above	* Reduced by Basic Filing Fee Paid			Fee Paid	SUBTOTAL (3)	\$0.0

Submitted By	Complete (if applicable)	
Name (Print/Type) Jonathan L. Klein	Registration No.: 41,119	Telephone: (301) 251-6015
	1	Date: November 16, 2001
Signature: / Rein		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wei et al.

Attorney Docket No.: PF268D1C1

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: Human Hematopoietic-Specific Protein

STATEMENT UNDER 37 C.F.R. § 1.821

Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on paper) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: November 16, 2001

Jonathan L. Klein

Attorney for Applicants

Reg. No. 41,119

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (301) 251-6015

JLK/CCB/ba